Challenges of Cancer Biomarker Profiling{A figure is presented}

European Urology

Volumn 52, Issue 6, 2007, Pages 1601-1609

  Bensalah, Karim ^a   Montorsi, Francesco ^b   Shariat, Shahrokh F ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Biomarker; Cancer; Cost; Immunohistochemistry; Prediction; Tissue

Indexed keywords

CA 125 ANTIGEN; CARBONATE DEHYDRATASE IX; ESTROGEN RECEPTOR; NUCLEAR MATRIX PROTEIN 22; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CLINICAL PRACTICE; DNA MICROARRAY; EARLY DIAGNOSIS; HUMAN; IMMUNOHISTOCHEMISTRY; ONCOGENE; PATENT; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY;

ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 35748947727     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.09.036     Document Type: Review

References (33)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. Egawa S., and Kuruma H. Search for biomarkers of aggressiveness in bladder cancer. Eur Urol 50 (2006) 20-22
3. Wolff A.C., Hammond M.E., Schwartz J.N., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25 (2007) 118-145
4. van Gils M.P., Stenman U.H., Schalken J.A., et al. Innovations in serum and urine markers in prostate cancer: current European research in the P-Mark project. Eur Urol 48 (2005) 1031-1041
5. Ilyin S.E., Belkowski S.M., and Plata-Salaman C.R. Biomarker discovery and validation: technologies and integrative approaches. Trends Biotechnol 22 (2004) 411-416
6. Hedenfalk I., Duggan D., Chen Y., et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med 344 (2001) 539-548
7. Andre F., and Pusztai L. Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy. Nat Clin Pract 3 (2006) 621-632
8. Azad N.S., Rasool N., Annunziata C.M., Minasian L., Whiteley G., and Kohn E.C. Proteomics in clinical trials and practice: present uses and future promise. Mol Cell Proteomics 5 (2006) 1819-1829
9. Belkowski S.M., Polkovitch D., and D'Andrea M.R. Synergistic approaches to clinical oncology biomarker discovery. Curr Top Med Chem 5 (2005) 1047-1051
10. Li G., Cuilleron M., Cottier M., et al. The use of MN/CA9 gene expression in identifying malignant solid renal tumors. Eur Urol 49 (2006) 401-405
11. Schnitt S.J. Traditional and newer pathologic factors. J Natl Cancer Inst Monogr 30 (2001) 22-26
12. Leppert J.T., Pantuck A.J., Figlin R.A., and Belldegrun A.S. The role of molecular markers in the staging of renal cell carcinoma. BJU Int 99 (2007) 1208-1211
13. Mulders P., Bleumer I., Debruyne F., and Oosterwijk E. Specific monoclonal antibody-based immunotherapy by targeting the RCC-associated antigen carbonic anhydrase-IX(G250/MN). Urologe A 43 Suppl 3 (2004) 146-147
14. Scher H.I., Mazumdar M., and Kelly W.K. Clinical trials in relapsed prostate cancer: defining the target. J Natl Cancer Inst 88 (1996) 1623-1634
15. Vicini F.A., Vargas C., Abner A., Kestin L., Horwitz E., and Martinez A. Limitations in the use of serum prostate specific antigen levels to monitor patients after treatment for prostate cancer. J Urol 173 (2005) 1456-1462
16. Simmons M.N., Stephenson A.J., and Klein E.A. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. Eur Urol 51 (2007) 1175-1184
17. Aus G. Second-line therapy after radical prostatectomy failure: for whom? When? How?. Eur Urol 51 (2007) 1155-1157 discussion 1157-8
18. Caulfield T.A., and Gold E.R. Genetic testing, ethical concerns, and the role of patent law. Clin Genet 57 (2000) 370-375
19. Benowitz S. European groups oppose Myriad's latest patent on BRCA1. J Natl Cancer Inst 95 (2003) 8-9
20. Srinivasan M., Sedmak D., and Jewell S. Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am J Pathol 161 (2002) 1961-1971
21. Cox M.L., Schray C.L., Luster C.N., et al. Assessment of fixatives, fixation, and tissue processing on morphology and RNA integrity. Exp Mol Pathol 80 (2006) 183-191
22. Kattan M.W., Shariat S.F., Andrews B., et al. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol 21 (2003) 3573-3579
23. Raaijmakers R., de Vries S.H., Blijenberg B.G., et al. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml. Eur Urol 52 (2007) 1358-1364
24. Pantuck A.J., Zisman A., and Belldegrun A.S. The changing natural history of renal cell carcinoma. J Urol 166 (2001) 1611-1623
25. Cady B., Stone M.D., Schuler J.G., Thakur R., Wanner M.A., and Lavin P.T. The new era in breast cancer. Invasion, size, and nodal involvement dramatically decreasing as a result of mammographic screening. Arch Surg 131 (1996) 301-308
26. Esrig D., Elmajian D., Groshen S., et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 331 (1994) 1259-1264
27. Malats N., Bustos A., Nascimento C.M., et al. p53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol 6 (2005) 678-686
28. Gutman S., and Kessler L.G. The US Food and Drug Administration perspective on cancer biomarker development. Nat Rev 6 (2006) 565-571
29. Mor G., Visintin I., Lai Y., et al. Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci U S A 102 (2005) 7677-7682
30. Sabatine M.S., Morrow D.A., de Lemos J.A., et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 105 (2002) 1760-1763
31. Shariat S.F., Tokunaga H., Zhou J., et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 22 (2004) 1014-1024
32. Shariat S.F., Zlotta A.R., Ashfaq R., Sagalowsky A.I., and Lotan Y. Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Mod Pathol 20 (2007) 445-459
33. Karam J.A., Lotan Y., Karakiewicz P.I., et al. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol 8 (2007) 128-136